Department of Oncology, Hospital General Universitario Gregorio Marañón, C/Doctor Esquerdo 46, 28007, Madrid, Spain.
Clin Transl Oncol. 2013 Jun;15(6):443-9. doi: 10.1007/s12094-012-0949-1. Epub 2012 Nov 10.
To report feasibility, tolerance, anatomical sites of upper abdominal locoregional recurrence and long-term outcome of gastric cancer patients treated with surgery and a component of intraoperative electron beam radiotherapy (IORT).
From January 1995 to December 2010, 32 patients with primary gastric adenocarcinoma treated with curative resection (R0) [total gastrectomy (n = 9; 28 %), subtotal (n = 23; 72 %) and D2 lymphadenectomy in all patients] and apparent disease confined to locoregional area [Stage: II (n = 15; 47 %), III (n = 17; 53 %)] were treated with a component of IORT (IORT applicator size 5-9 cm in diameter, dose 10-15 Gy, beam energy 6-5 MeV) over the celiac axis and peripancreatic nodal areas. Sixteen (50 %) patients also received adjuvant treatment (external beam radiotherapy n = 6, chemoradiation n = 9, chemotherapy alone n = 1).
With a median follow-up time of 40 months (range, 2-60), locoregional recurrence was observed in five (16 %) patients (4 nodal in hepatic hilum and 1 anastomotic). Only pN1 patients developed locoregional relapse. No recurrence was observed in the IORT-treated target volume (celiac trunk and peripancreatic nodes). Overall survival at 5 years was 54.6 % (95 % CI: 48.57-60.58). Postoperative mortality was 6 % (n = 2) and postoperative complications 19 % (n = 6).
It is feasible to integrate IORT as a component of radiotherapy in combined modality therapy of gastric cancer. Local control is high in the radiation boosted area, but marginal regional extension (in particular, involving the hepatic hilum) might be considered as part of the anatomic IORT target volume at risk in pN+ patients.
本研究旨在报告胃癌患者接受手术联合术中电子束放疗(IORT)治疗的可行性、耐受性、上腹部区域性复发的解剖部位和长期疗效。
从 1995 年 1 月至 2010 年 12 月,对 32 例接受根治性切除术(R0)[全胃切除术(n=9;28%)、次全胃切除术(n=23;72%),所有患者均行 D2 淋巴结清扫术]和明显局限于区域性疾病的原发性胃腺癌患者(IORT 应用器直径 5-9cm,剂量 10-15Gy,束能 6-5MeV)进行治疗。所有患者均在腹腔干和胰腺周围淋巴结区域接受 IORT 治疗。16 例(50%)患者还接受了辅助治疗(外照射放疗 n=6,放化疗 n=9,单纯化疗 n=1)。
中位随访时间为 40 个月(范围 2-60 个月),5 例(16%)患者出现区域性复发(肝门 4 例,吻合口 1 例)。仅 pN1 患者发生区域性复发。在 IORT 治疗的靶区(腹腔干和胰腺周围淋巴结)未观察到复发。5 年总生存率为 54.6%(95%CI:48.57-60.58)。术后死亡率为 6%(n=2),术后并发症为 19%(n=6)。
将 IORT 作为胃癌综合治疗的放疗组成部分是可行的。在放疗增强区域局部控制效果较好,但边缘区域扩展(特别是累及肝门)可能被认为是 pN+患者 IORT 靶区的解剖风险部位。